Enanta Pharmaceuticals Inc
SWB:9EP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
E
|
Enanta Pharmaceuticals Inc
SWB:9EP
|
US |
|
C
|
Corvus Pharmaceuticals Inc
SWB:C17
|
US |
|
H
|
Haseeb Waqas Sugar Mills Ltd
KAR:HWQS
|
PK |
|
Spring Valley Acquisition Corp III
NASDAQ:SVAC
|
US |
|
S
|
Spectra Products Inc
OTC:SPKTF
|
CA |
|
L
|
LongFin Corp
OTC:LFIN
|
US |
|
Bionik Laboratories Corp
OTC:BNKL
|
CA |
|
N
|
Nisshinbo Holdings Inc
F:NBO
|
JP |
|
C
|
Commvault Systems Inc
SWB:D6I
|
US |
|
E
|
Emergent Metals Corp
OTC:EGMCF
|
CA |
|
X
|
Xunlei Ltd
XMUN:4XN
|
CN |
|
K
|
Kaji Technology Corp
TSE:6391
|
JP |
|
C
|
C-Tech United Corp
TPEX:3625
|
TW |
|
Wavestone SA
LSE:0G1T
|
FR |
|
Iffe Futura SA
MAD:NAT
|
ES |
Bankruptcy Probability
Enanta Pharmaceuticals Inc's probability of bankruptcy is Hidden . The solvency score is Hidden .
We take all the information about a company's solvency, such as how easily it can pay interest on outstanding debt, how much cash it has, the amount of debt, and more, and use it to estimate the probability of bankruptcy.
Solvency Ratios
Solvency Ratios Comparison
Enanta Pharmaceuticals Inc Competitors
| Country | Company | Market Cap | D/E | D/A |
Interest Coverage |
Altman Z-Score |
Quick Ratio |
Current Ratio |
Cash Ratio |
||
|---|---|---|---|---|---|---|---|---|---|---|---|
| US |
|
Enanta Pharmaceuticals Inc
NASDAQ:ENTA
|
410m USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| JP |
|
Takara Bio Inc
TSE:4974
|
120.4T JPY |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
453.2B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
236.5B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
187.4B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
138.4B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
85.6B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
54.4B EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
82.9B AUD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Enanta Pharmaceuticals Inc's probability of bankruptcy is Hidden .
The probability of bankruptcy is estimated using credit risk models that assess financial health, debt levels, interest coverage, and other solvency indicators.
As of the latest report, Enanta Pharmaceuticals Inc has total debt of 89.6m USD. This includes both short-term (0 USD) and long-term (89.6m USD) debt.
You can find a full breakdown on its Balance Sheet.
